Excess Mortality Higher in Younger Patients With MPNs vs Older Patients

[EPguy]

Another ASH 2021 report.

<<(this result) could be linked to age-biased risk assessment and guidelines that recommend lower intensity treatment for young patients.>> Many discussions on MPN Voice about whether to start treatment early.

This suggests the traditional "watch and wait" for under 60's may be a bad idea. The data in my post from Dr. Harrison supports at least HCT control for all I believe.

<<Excess all-cause mortality was greater in younger patients (<60 years) compared to older patients with

ET (2.75 vs 1.82; P <.001),

PV (3.16 vs 1.92, P <.001), and

PMF (10.6 vs 5.73; P <.001).>>

The other data are less obvious to me but the author seems clear on the implications.

cancertherapyadvisor.com/ho...

[Loooonglife]

Thank you for posting these cutting edge research updates. This work is so important and illuminates the path forward to better treatment strategies and more effective medicines in the hopefully near future!

[Minu68]

thanks for this, interesting read. I have ET JAK2 and am classed as a younger person, being 53b years old, so its very relevant research for me to be aware of.

[Faith33]

Thanks for this intersting post. It sounds very interesting especially about treatments. . I wonder if I could have the link or full name of the report so I can read it? thanks ETguy !

[cpa09gp in reply to Faith33]

The link is already in the post, which lists the full reference as:

Abu-Zeinah K, Saadeh K, Silver RT, et al. Excess mortality in young patients with myeloproliferative neoplasms. Presented at ASH 2021; December 11-14, 2021. Abstract 235.

[Leighcox85]

I was diagnosed with primary mylefibrosis at age 24 iam 36 but my original hemp did use the watch amd wait only starting treatment when my bone marrow was gone and they couldn’t get a sample so iam very interested to read this thank you and merry Christmas x

[EPguy in reply to Leighcox85]

There is another quote in one of my posts with an expert saying "..the notion of treating these diseases only when far advanced is antithetical to treating other forms of cancer" Problem is we didn't have "cancer" till recent times, just a "blood disorder"

For intermediate- or high-risk MF patients:

<<These data suggest that combination therapy with ruxolitinib and interferon may prove to be an effective treatment>>

ncbi.nlm.nih.gov/pmc/articl...

Has your Dr discussed this?

Has your Dr also discussed SCT?

[Bluetop]

Thanks for picking that one up.